Source: International Congress 2016 – ILD pathogenesis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Lutz Wollin (Biberach Riss, Germany), Elizabeth Redente, Martin Aguilar, Luc Lalire, Benjamin Edelman, Lutz Wollin, David Riches. Nintedanib reduces fibrotic markers in the lung in a model of rheumatoid arthritis associated interstitial lung disease. Eur Respir J 2016; 48: Suppl. 60, 3089

Member's Comments

No comment yet.

Related content which might interest you: Early detection of subclinical interstitial lung disease in patients with rheumatoid arthritis and effect of methotrexate therapy Source: International Congress 2014 – ILDs 4 Year: 2014 Co-morbidities and cause of death in patients with rheumatoid arthritis associated interstitial lung disease Source: International Congress 2015 – Connective tissue disorders Year: 2015 The value of biomarkers in the rheumatoid arthritis related interstitial pneumonia Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Rituximab in severe, treatment-refractory interstitial lung disease Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Genomic comparison of fibrotic rheumatoid arthritis-associated ILD and idiopathic pulmonary fibrosis Source: International Congress 2015 – Connective tissue disorders Year: 2015 Analysis of inflammatory networks in interstitial lung disease in patients with rheumatoid arthritis Source: International Congress 2016 – Connective tissue disorders Year: 2016 Interstitial lung abnormalities a risk factor for rheumatoid arthritis interstitial lung disease progression: what's new Source: Breathe, 16 (4) 200223; 10.1183/20734735.0223-2020 Year: 2020 "Cyclophosphamide for the treatment of inflammation driven fibrotic interstitial lung disease" Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Addition of respiratory hospitalizations 24weeks prior to the ILD-GAP model to predict mortality in chronic interstitial lung disease Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Are risk predicting models useful for estimating survival in rheumatoid arthritis-associated interstitial lung disease? Source: International Congress 2016 – Connective tissue disorders Year: 2016 Characteristics and predictors of outcome in rheumatoid arthritis related ILD Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Interstitial lung disease in a single center inception cohort of early rheumatoid arthritis patients Source: International Congress 2015 – Connective tissue disorders Year: 2015 The role of detection of myositis specific and associated antibodies in Japanese patient with interstitial lung disease Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015 Methotrexate and rheumatoid arthritis associated interstitial lung disease Source: Eur Respir J, 57 (2) 2000337; 10.1183/13993003.00337-2020 Year: 2021 Rituximab in severe, progressive interstitial lung disease Source: International Congress 2016 – Connective tissue disorders Year: 2016 Using the ILD-GAP model to predict mortality in chronic interstitial lung disease Source: International Congress 2015 – IIPs: orphan Year: 2015 Interstitial lung disease in patients with rheumatoid arthritis Source: Annual Congress 2008 - Sarcoidosis and other interstitial lung diseases Year: 2008 Prognostic factors of interstitial lung disease associated with primary Sjögren's syndrome Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 The diagnostic of the respiratory pathology in patients with rheumatoid arthritis (RA) Source: International Congress 2016 – The best clinical approach to lung diseases Year: 2016